Quick answer
What is Ibutamoren?
Built from index records dated 2026-10-09 to 2026-10-13 Compiled by an automated pipeline, checked by The Peptide Observer editorial desk. No qualified clinical reviewer. How this site works
Ibutamoren is not a peptide, grouped on this site under Growth hormone secretagogues, and the 12 research records kept here are 1 from a study in rats or mice, 2 from trials in people and 9 that do not state what kind of study it is.
The literature search returned 30 records. This site keeps 12 of them, which is 40 per cent of what came back.
What it is
Ibutamoren is indexed here despite not being a peptide, because the same research literature and the same searches cover it. This site puts it in the Growth hormone secretagogues group.
A non-peptide agonist at the ghrelin receptor, the growth hormone secretagogue receptor.[1, 2]
Stated in the titles of the cited 2021 Nature Communications and 2001 Clinical Pharmacology and Therapeutics papers.
What kind of records
A small number of the records kept here are trials in people.
That sentence is produced by counting, not by reading. What was counted: 2 interventional human trial records among 12 indexed records.
What this does not settle
- What it does in a body. Counting records is not reading them, and nothing here has been read in full.
- Whether it causes harm. No adverse-effect row was taken from any source for this entry.
- How long it lasts. No pharmacokinetics source was retrieved for this entry.
- What the other 18 retrieved records say. They are not in this index.
The longer explanation
Where this comes from
The records cited above, in full.
- Structural basis of human ghrelin receptor signaling by ghrelin and the synthetic agonist ibutamoren. Nat Commun (2021). pmid:34737341
- Effects of oral administration of ibutamoren mesylate, a nonpeptide growth hormone secretagogue, on the growth hormone-insulin-like growth factor I axis in growth hormone-deficient children. Clin Pharmacol Ther (2001). pmid:11452249